003060 — Aprogen Biologics Income Statement
0.000.00%
Last trade - 00:00- KR₩46bn
- KR₩292bn
- KR₩73bn
Annual income statement for Aprogen Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 56,482 | 65,190 | 87,364 | 67,378 | 73,226 |
| Cost of Revenue | |||||
| Gross Profit | 25,445 | 27,286 | -11,663 | -7,579 | -27,032 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 62,420 | 71,895 | 151,321 | 137,483 | 198,506 |
| Operating Profit | -5,938 | -6,704 | -63,957 | -70,105 | -125,280 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 9,831 | 14,881 | -113,383 | -104,980 | -169,378 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 9,151 | 13,621 | -115,330 | -104,980 | -168,297 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 8,103 | 12,639 | -118,270 | -104,979 | -170,331 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 8,103 | 12,639 | -118,270 | -104,979 | -170,331 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2,878 | 3,900 | -20,653 | -10,460 | -9,732 |
| Dividends per Share |